show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.
Pfizer said on Wednesday there had been 170 cases of the disease in its trial of more 43,000 volunteers, of which 162 were observed in the placebo arm and 8 were in the vaccine group.It also said the vaccine was well-tolerated and that side effects were mostly mild to moderate and cleared up quickly.
The results come as the virus is running rampant in the United States, Europe and elsewhere, placing an enormous strain on healthcare systems with record numbers of new cases and hospitalizations. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” Pfizer CEO Albert Bourla said in a statement.
When we gonna get some!?